the progress in development during the spring and the path to the planned launch in 2026. Finally, we learn that the capital from series TO6 and TO7 warrants is expected to be sufficient until commercialization.
Watch the interview with Prolight Diagnostics vd Ulf Bladin below.
BioStock is a news service and does not provide investment advice, does not mediate any investment orders and does not take any responsibility for actions and/or any loss or damage of any kind based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor. The content of BioStock's news and analyses is independent, but as BioStock's operations are partly financed by companies in the industry, the BioStock website may contain news about companies from which BioStock has received funding.
This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the warrant and more information about the company have been disclosed in the above-mentioned company's website.
